MDxHealth (MDXH) to Release Quarterly Earnings on Wednesday

MDxHealth (NASDAQ:MDXH) is expected to be issuing its Q3 2025 results after the market closes on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $24.1080 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. The company had revenue of $26.60 million during the quarter, compared to analyst estimates of $26.60 million. On average, analysts expect MDxHealth to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MDxHealth Trading Down 1.7%

MDxHealth stock opened at $4.76 on Wednesday. The company’s fifty day simple moving average is $4.20 and its 200-day simple moving average is $2.93. The company has a quick ratio of 1.22, a current ratio of 1.31 and a debt-to-equity ratio of 13.81. MDxHealth has a 12 month low of $1.35 and a 12 month high of $5.33. The stock has a market cap of $225.09 million, a P/E ratio of -5.41 and a beta of 1.65.

Analyst Ratings Changes

A number of research firms recently issued reports on MDXH. Wall Street Zen raised MDxHealth to a “hold” rating in a research report on Saturday, August 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. Finally, Craig Hallum assumed coverage on MDxHealth in a research note on Thursday, July 17th. They set a “buy” rating and a $8.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.00.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.